Comparative Pharmacology
Head-to-head clinical analysis: SODIUM LACTATE 1 6 MOLAR IN PLASTIC CONTAINER versus SYNOVALYTE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM LACTATE 1 6 MOLAR IN PLASTIC CONTAINER versus SYNOVALYTE IN PLASTIC CONTAINER.
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER vs SYNOVALYTE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium lactate is a source of bicarbonate precursor. It is metabolized to bicarbonate in the liver, which buffers metabolic acidosis, restoring acid-base balance.
SYNOVALYTE is a hyaluronan preparation that acts as a viscoelastic supplement, restoring the rheological properties of synovial fluid in osteoarthritic joints. It provides lubrication and shock absorption, and may exert anti-inflammatory and analgesic effects through modulation of synovial fluid viscosity and interaction with hyaluronan receptors.
Intravenous infusion: The typical adult dose is 300-500 mL of 1/6 Molar sodium lactate solution (approximately 167 mEq/L each of sodium and lactate, 1 L contains 167 mEq of sodium and lactate) administered as a continuous intravenous infusion at a rate of 0.5-2.5 mL/kg/hour, adjusted based on the severity of acidosis and clinical response. Maximum infusion rate: 2.5 mL/kg/hour.
Intra-articular injection: 2 mL per joint once weekly for 3 weeks.
None Documented
None Documented
30–60 minutes for lactate conversion; bicarbonate component determined by CO2 excretion.
Not applicable; components (sodium, chloride, lactate) are endogenous and rapidly redistributed; lactate half-life ~5-10 minutes in normal hepatic function.
Primarily renal as bicarbonate and lactate; <5% unchanged.
Renal excretion of sodium, chloride, and lactate; not metabolized; elimination routes not quantified as it is a crystalloid solution.
Category C
Category C
Electrolyte Solution
Electrolyte Solution